A NEW Swedish study has found that menopausal hormone therapy (MHT) may be associated with an increased risk of developing ...

Ocular manifestations of SLE are common and may lead to permanent blindness from the underlying disease or therapeutic side effects. Keratoconjunctivitis sicca is the most common manifestation.

SLE: Systemic lupus erythematosus. Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life.

Autoimmune disorders in children can cause symptoms often mistaken for common childhood illnesses. More precise diagnoses and ...

Objective Hypertension (HTN) is common in systemic lupus erythematosus (SLE), representing a key risk factor for cardiovascular and renal disease. We described HTN treatment patterns in SLE, evaluated ...

National Library of Medicine. Systemic lupus erythematosus. Lupus Foundation of America. Complementary and alternative medicine for lupus. Centers for Disease Control and Prevention. Symptoms of lupus ...

New Study Shows Certain Combinations of Antiviral Proteins Are Responsible for Lupus Symptoms and Affect ... Incurable Autoimmune Disease Systemic Lupus Erythematosus (SLE): New Genetic Findings ...

People with lupus are at an increased risk of depression. Lupus is a chronic condition with recurring symptoms that can ...

SLE patients have also been evaluated for effect of previous hysterectomy (with and without concomitant oophorectomy). SLE patients (n = 3389) who had undergone hysterectomy were less likely to ...

Uncertainty about future care and life impacts were among the top concerns for patients with psoriatic arthritis, but not for physicians, who highly prioritized individual symptoms, according to ...

Systemic lupus erythematosus (SLE ... This disrupts your sleep, which in turn can lead to symptoms such as daytime sleepiness and restlessness. Learn about lifestyle remedies for OSA.

AliveDx’s CE mark for the systematic autoimmune rheumatic disease (SARD) assay marks its fifth approval in the past 18 months ...